オープン アクセスを義務付けられた論文 - Stephen Wiviott詳細
一般には非公開: 9 件
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset …
MS Sabatine, LA Leiter, SD Wiviott, RP Giugliano, P Deedwania, ...
The lancet Diabetes & endocrinology 5 (12), 941-950, 2017
委任: National Institute for Health Research, UK
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 …
L Mauri, DJ Kereiakes, SLT Normand, SD Wiviott, DJ Cohen, DR Holmes, ...
American heart journal 160 (6), 1035-1041. e1, 2010
委任: US National Institutes of Health
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or …
SR Wilson, MS Sabatine, SD Wiviott, KK Ray, JA De Lemos, S Zhou, ...
American heart journal 161 (6), 1147-1155. e1, 2011
委任: US National Institutes of Health
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel
ET Carreras, W Hochholzer, AL Frelinger III, F Nordio, ML O’Donoghue, ...
Thrombosis and haemostasis 116 (07), 69-77, 2016
委任: US National Institutes of Health
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: analysis from the …
YJ Shimada, S Bansilal, SD Wiviott, RC Becker, RA Harrington, ...
American heart journal 177, 1-8, 2016
委任: US National Institutes of Health, American Heart Association
Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to …
PG Steg, SR Mehta, CV Pollack Jr, C Bode, C Gaudin, K Fanouillere, ...
American heart journal 164 (6), 817-824. e13, 2012
委任: National Institute of Health and Medical Research, France
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF–TIMI 48
TA Zelniker, CT Ruff, SD Wiviott, JJ Blanc, R Cappato, F Nordio, ...
European Heart Journal: Acute Cardiovascular Care 8 (2), 176-185, 2019
委任: German Research Foundation
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full-and half-dose edoxaban vs. warfarin: insights from …
MP Bonaca, EM Antman, JW Cunningham, SD Wiviott, SA Murphy, ...
European Heart Journal-Cardiovascular Pharmacotherapy 8 (7), 695-706, 2022
委任: US National Institutes of Health, American Heart Association
ED administration of thienopyridines in non–ST-segment elevation myocardial infarction: results from the NCDR
DB Diercks, MC Kontos, JE Hollander, BE Mumma, DJN Holmes, ...
The American Journal of Emergency Medicine 31 (7), 1005-1011, 2013
委任: US National Institutes of Health
一般公開: 88 件
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ...
New England Journal of Medicine 380 (4), 347-357, 2019
委任: German Research Foundation
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SD Wiviott, ...
New England journal of medicine 376 (18), 1713-1722, 2017
委任: UK Medical Research Council, National Institute for Health Research, UK
Edoxaban versus warfarin in patients with atrial fibrillation
RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ...
New England Journal of Medicine 369 (22), 2093-2104, 2013
委任: UK Medical Research Council
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome …
TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ...
The Lancet 393 (10166), 31-39, 2019
委任: German Research Foundation
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
L Mauri, DJ Kereiakes, RW Yeh, P Driscoll-Shempp, DE Cutlip, PG Steg, ...
New England Journal of Medicine 371 (23), 2155-2166, 2014
委任: US National Institutes of Health
Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis
MG Silverman, BA Ference, K Im, SD Wiviott, RP Giugliano, SM Grundy, ...
Jama 316 (12), 1289-1297, 2016
委任: US National Institutes of Health
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
JL Mega, T Simon, JP Collet, JL Anderson, EM Antman, K Bliden, ...
Jama 304 (16), 1821-1830, 2010
委任: US National Institutes of Health, National Institute of Health and Medical …
Coronary CT angiography versus standard evaluation in acute chest pain
U Hoffmann, QA Truong, DA Schoenfeld, ET Chou, PK Woodard, ...
New England Journal of Medicine 367 (4), 299-308, 2012
委任: US National Institutes of Health
Effects of anacetrapib in patients with atherosclerotic vascular disease
HPS3/TIMI55–Reveal Collaborative Group
New England Journal of Medicine 377 (13), 1217-1227, 2017
委任: Versus Arthritis, UK, British Heart Foundation, UK Medical Research Council …
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
JL Mega, SL Close, SD Wiviott, L Shen, JR Walker, T Simon, EM Antman, ...
The Lancet 376 (9749), 1312-1319, 2010
委任: US National Institutes of Health
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal …
TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ...
Circulation 139 (17), 2022-2031, 2019
委任: German Research Foundation
公開と助成金に関する情報は、コンピュータ プログラムによって自動的に決定されます